Editorial: Feeling better about <scp>NASH</scp>—Authors' reply-Reference-Cited by-同舟云学术

Editorial: Feeling better about NASH—Authors' reply

Published:2023-07-27 Issue:4 Volume:58 Page:484-485
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Romero‐Gómez Manuel¹^ORCID,Armstrong Matthew J.²^ORCID,Funuyet‐Salas Jesús³^ORCID,Mangla Kamal Kant⁴,Ladelund Steen⁴,Sejling Anne‐Sophie⁴,Shrestha Ichhya⁴,Sanyal Arun J.⁵^ORCID

Affiliation:

1. UCM Digestive Diseases and CIBEREHD Virgen del Rocío University Hospital Institute of Biomedicine of Seville (CSIC/HUVR/US) University of Seville Seville Spain

2. Department of Hepatology and Liver Transplantation Queen Elizabeth University Hospital Birmingham Birmingham UK

3. Department of Personality Assessment and Psychological Treatment Faculty of Psychology University of Seville Seville Spain

4. Novo Nordisk A/S Søborg Denmark

5. Virginia Commonwealth University School of Medicine Richmond Virginia USA

Abstract

LINKED CONTENTThis article is linked to Romero Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.17598 and https://doi.org/10.1111/apt.17621

Funder

Novo Nordisk

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17641

Reference7 articles.

1. Editorial: Feeling better about NASH

2. Improved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial

3. Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis

4. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction

5. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases